12 September 2014 in JNCI: Journal of the National Cancer Institute
National legislation is under consideration that would require women with mammographically dense breasts to be informed of their breast density and encouraged to discuss supplemental breast cancer screening with their health care providers. The number of US women potentially affected by this legislation is unknown. We determined the mammographic breast density distribution by age and body mass index (BMI) using data from 1518 599 mammograms conducted from 2007 through 2010 at mammography facilities in the Breast Cancer Surveillance Consortium (BCSC). We applied these breast density distributions to age- and BMI-specific counts of the US female population derived from the 2010 US Census and the National Health and Nutrition Examination Survey (NHANES) to estimate the number of US women with dense breasts. Overall, 43.3% (95% confidence interval [CI] = 43.1% to 43.4%) of women 40 to 74 years of age had heterogeneously or extremely dense breasts, and this proportion was inversely associated with age and BMI. Based on the age and BMI distribution of US women, we estimated that 27.6 million women (95% CI = 27.5 to 27.7 million) aged 40 to 74 years in the United States have heterogeneously or extremely dense breasts. Women aged 40 to 49 years (N = 12.3 million) accounted for 44.3% of this group. The prevalence of dense breasts among US women of common breast cancer screening ages exceeds 25 million. Policymakers and healthcare providers should consider this large prevalence when debating breast density notification legislation and designing strategies to ensure that women who are notified have opportunities to evaluate breast cancer risk and discuss and pursue supplemental screening options if deemed appropriate.
1 September 2012 in Obstetrics & Gynecology
Short-term declines in postmenopausal hormone use were observed after the Women's Health Initiative trial results in 2002. Although concerns about the trial's generalizability have been expressed, long-term trends in hormone use in a nationally representative sample have not been reported. We sought to evaluate national trends in the prevalence of hormone use and to assess variation by type of formulation and patient characteristics. We examined postmenopausal hormone use during 1999–2010 using cross-sectional data from 10,107 women aged 40 years and older in the National Health and Nutrition Examination Survey. In 1999–2000, the prevalence of oral postmenopausal hormone use was 22.4% (95% confidence interval [CI] 19.0–25.8) overall, 13.3% (95% CI 11.0–15.5) for estrogen only, and 8.3% (95% CI 6.2–10.4) for estrogen plus progestin. A sharp decline in use of all formulations occurred in 2003–2004, when the overall prevalence decreased to 11.9% (95% CI 9.6–14.2). This decline was initially limited to non-Hispanic whites; use among non-Hispanic blacks and Hispanics did not decline substantially until 2005–2006. Hormone use continued to decline through 2009–2010 across all patient demographic groups, with the current prevalence now at 4.7% (95% CI 3.3–6.1) overall, 2.7% (95% CI 1.9–3.4) for estrogen only, and 1.7% (95% CI 0.7–2.7) for estrogen plus progestin. Patient characteristics currently associated with hormone use include history of hysterectomy, non-Hispanic white race or ethnicity, and income. Postmenopausal hormone use in the United States has declined in a sustained fashion to low levels across a wide variety of patient subgroups. II
3 February 2015 in Annals of Internal Medicine
NRNicolien T. van Ravesteyn
Nicolien T. van Ravesteyn
+8
Many states have laws requiring mammography facilities to tell women with dense breasts and negative results on screening mammography to discuss supplemental screening tests with their providers. The most readily available supplemental screening method is ultrasonography, but little is known about its effectiveness. To evaluate the benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Comparative modeling with 3 validated simulation models. Surveillance, Epidemiology, and End Results Program; Breast Cancer Surveillance Consortium; and medical literature. Contemporary cohort of women eligible for routine screening. Lifetime. Payer. Supplemental ultrasonography screening for women with dense breasts after a negative screening mammography result. Breast cancer deaths averted, quality-adjusted life-years (QALYs) gained, biopsies recommended after a false-positive ultrasonography result, and costs. Supplemental ultrasonography screening after a negative mammography result for women aged 50 to 74 years with heterogeneously or extremely dense breasts averted 0.36 additional breast cancer deaths (range across models, 0.14 to 0.75), gained 1.7 QALYs (range, 0.9 to 4.7), and resulted in 354 biopsy recommendations after a false-positive ultrasonography result (range, 345 to 421) per 1000 women with dense breasts compared with biennial screening by mammography alone. The cost-effectiveness ratio was $325 000 per QALY gained (range, $112 000 to $766 000). Supplemental ultrasonography screening for only women with extremely dense breasts cost $246 000 per QALY gained (range, $74 000 to $535 000). The conclusions were not sensitive to ultrasonography performance characteristics, screening frequency, or starting age. Provider costs for coordinating supplemental ultrasonography were not considered. Supplemental ultrasonography screening for women with dense breasts would substantially increase costs while producing relatively small benefits. National Cancer Institute.
4 October 2016 in Annals of Internal Medicine
OCon behalf of the PROSPR Consortium*
on behalf of the PROSPR Consortium*
+9
About half of the United States currently has legislation requiring radiology facilities to disclose information on mammographic breast density to women, and many include language recommending disc... Background: About half of the United States has legislation requiring radiology facilities to disclose mammographic breast density information to women, often with language recommending discussion ...
1 January 2015 in American Journal of Obstetrics and Gynecology
8 November 2010 in Cancer
BACKGROUND: Women who live in geographic areas with high poverty rates and low levels of education experience poorer survival after a breast cancer diagnosis than women who live in communities with indicators of high socioeconomic status (SES). However, very few studies have examined individual‐level SES in relation to breast cancer survival or have assessed the contextual role of community‐level SES independent of individual‐level SES.METHODS: The authors of this report examined both individual‐level and community‐level SES in relation to breast cancer survival in a population‐based cohort of women ages 20 to 69 years who were diagnosed with breast cancer in Wisconsin between 1995 and 2003 (N = 5820).RESULTS: Compared with college graduates, women who had no education beyond high school were 1.39 times more likely (95% confidence interval [CI], 1.10‐1.76) to die from breast cancer. Women who had household incomes <2.5 times the poverty level were 1.46 times more likely (95% CI, 1.10‐1.92) to die from breast cancer than women who had household incomes ≥5 times the poverty level. Adjusting the analysis for use of screening mammography, disease stage at diagnosis, and lifestyle factors eliminated the disparity by income, but the disparity by education persisted (hazard ratio [HR], 1.27; 95% CI, 0.99‐1.61). In multilevel analyses, low community‐level education was associated with increased breast cancer mortality even after adjusting for individual‐level SES (HR, 1.57; 95% CI, 1.09‐2.27 for ≥20% vs <10% of adults without a high school degree).CONCLUSIONS: The current results indicated that screening and early detection explain some of the disparity according to SES, but further research will be needed to understand the additional ways in which individual‐level and community‐level education are associated with survival. Cancer 2011. © 2010 American Cancer Society.